
The ORIGIN 3 analysis met all prespecified endpoints, as Vera plans a supplemental FDA filing later this year.
Vera Therapeutics said its TRUTAKNA treatment met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial in adults with IgA nephropathy. The study had already met its primary endpoint, reducing proteinuria at 36 weeks.
The company reported statistically significant results for kidney-function measures and reduced risk of composite kidney disease progression events. It said the drug’s safety profile was generally comparable to placebo. The indication is currently under accelerated approval based on proteinuria reduction; whether TRUTAKNA slows long-term kidney-function decline has not been established.
Vera plans to submit a supplemental application to the FDA in the fourth quarter of 2026, with full approval expected in 2027, the company said. As of 16:19 UTC on Oct. 22, Vera shares traded at $30.43, down 2.47% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.